Effects of the novel dopamine DA2-receptor agonist carmoxirole (EMD 45609) on noradrenergic and purinergic neurotransmission in rat isolated kidney.
The effects of the classical dopamine DA2-receptor agonist quinpirole (LY 171555) and the recently characterized DA2-receptor agonist, carmoxirole (EMD 45609), on neurotransmission in rat isolated kidney were investigated. After preincubation with 3H-noradrenaline, the renal nerves were electrically stimulated. The stimulation induced (S-I) outflow of radioactivity was taken as an index of noradrenaline release. Quinpirole (0.3 mumol/l) inhibited S-I outflow of radioactivity and pressor-responses to renal nerve stimulation (RNS) at 1 Hz. Both effects of quinpirole were blocked by the DA2-receptor antagonist S(-)-sulpiride (10 mumol/l). The alpha 1, alpha 2-adrenoceptor antagonist phentolamine (1 mumol/l) did not block the inhibitory effect of quinpirole. Carmoxirole (0.003 and 0.03 mumol/l) did not alter and carmoxirole (0.3 mumol/l) even enhanced S-I outflow of radioactivity, however, pressor responses to RNS were markedly reduced by carmoxirole (0.003-0.3 mumol/l). Pressor responses to RNS were also markedly reduced by the alpha 1-adrenoceptor antagonist prazosin (0.1 mumol/l). Carmoxirole (0.3 mumol/l), prazosin (0.1 mumol/l) and phentolamine (1 mumol/l) totally abolished pressor responses to exogenous noradrenaline (0.05 mumol/l). In contrast, quinpirole (0.3 mumol/l) did not alter pressor responses to exogenous noradrenaline (0.05 mumol/l). Furthermore, carmoxirole (0.003-0.3 mumol/l) markedly reduced pressor responses induced by the alpha 1-adrenoceptor agonist methoxamine (1 mumol/l) but even the highest concentration of carmoxirole (0.3 mumol/l) had no effect on pressor responses induced by bolus injections of either neuropeptide Y (1.5 ng) or angiotensin II (1 ng). Phentolamine (1 mumol/l) by itself markedly enhanced S-I outflow of radioactivity and pressor responses to RNS were virtually unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
Rump
L C
LC
Medizinische Universitätsklinik Freiburg, Innere Medizin IV, Federal Republic of Germany.
Wilde
K
K
Bohmann
C
C
Schollmeyer
P
P
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D015259:Dopamine Agents / Q000494:pharmacology*; D004873:Ergolines / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000294:innervation*; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology / Q000502:physiology*; D010646:Phentolamine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011687:Purines / Q000378:metabolism*; D011725:Pyridines / Q000494:pharmacology*; D019257:Quinpirole; D051381:Rats; D011919:Rats, Inbred Strains; D009435:Synaptic Transmission / Q000187:drug effects*; D014316:Tritium
D015259:Dopamine Agents; D004873:Ergolines; D007211:Indoles; D011687:Purines; D011725:Pyridines; D014316:Tritium; D019257:Quinpirole; D000255:Adenosine Triphosphate; C071485:carmoxirole; C002630:alpha,beta-methyleneadenosine 5'-triphosphate; D009638:Norepinephrine; D011224:Prazosin; D010646:Phentolamine